If you have been reading about NMNAT and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
| Property | Value | Notes |
|---|---|---|
| Chemical name | beta-Nicotinamide mononucleotide | Free acid and salt forms share the core structure. |
| Molecular formula | C11H15N2O8P | Calculated for the free acid; salt forms add counterions. |
| Molar mass | 334.22 g/mol | Approximate value for the free acid form. |
| Appearance | White to off-white powder | Color and texture can vary with purity and salt form. |
| Solubility | Water-soluble | Typically soluble in aqueous media; less soluble in nonpolar solvents. |
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
=== Myopathic === Bethlem myopathy 2, formerly known as Myopathic EDS (mEDS), is characterized by three major criteria: congenital muscle hypotonia and/or muscle atrophy that improves with age, proximal joint contractures of the knee, hip, and elbow, and hypermobility of distal joints (ankles, wrists, feet, and hands). Four minor criteria may also contribute to a diagnosis of mEDS. This disorder can be inherited through either an autosomal dominant or an autosomal recessive pattern. Molecular testing must be completed to verify that mutations in the COL12A1 gene are present; if not, other collagen-type myopathies should be considered.
While samples of plutonium were available in small quantities and being handled by researchers, no one knew what health effects this might have. Plutonium handling mishaps occurred in 1944, causing alarm in the Manhattan Project leadership as contamination inside and outside the laboratories was becoming an issue. In August 1944, chemist Donald Mastick was sprayed in the face with a solution of plutonium chloride, causing him to accidentally swallow some. Nose swipes taken of plutonium researchers indicated that plutonium was being breathed in. Lead Manhattan Project chemist Glenn Seaborg, discoverer of many transuranium elements including plutonium, urged that a safety program be developed for plutonium research. In a memo to Robert Stone at the Chicago Met Lab, Seaborg wrote "that a program to trace the course of plutonium in the body be initiated as soon as possible ... [with] the very highest priority." This memo was dated January 5, 1944, prior to many of the contamination events of 1944 in Building D where Mastick worked. Seaborg later claimed that he did not at all intend to imply human experimentation in this memo, nor did he learn of its use in humans until far later due to the compartmentalization of classified information. With bomb-grade enriched plutonium-239 destined for critical research and for atomic weapon production, plutonium-238 was used in early medical experiments as it is unusable as atomic weapon fuel. However, 238Pu is far more dangerous than 239Pu due to its short half-life and being a strong alpha-emitter.
"Neats" hope that intelligent behaviour is described using simple, elegant principles (such as logic or optimisation). "Scruffies" expect that it necessarily requires solving a large number of unrelated problems. Neats defend their programs with theoretical rigour, scruffies rely mainly on incremental testing to see if they work. This issue was actively discussed in the 1970s and 1980s. The rise of deep learning may represent a shift toward the scruffies.
On 19 November, the communists—meeting in Mukachevo—issued a resolution requesting separation of Subcarpathian Ruthenia from Czechoslovakia and incorporation into the Ukrainian Soviet Socialist Republic. On 26 November, the Congress of National Committees unanimously accepted the resolution of the communists. The congress elected the National Council and instructed that a delegation be sent to Moscow to discuss union. The Czechoslovak delegation was asked to leave Subcarpathian Ruthenia. Negotiations between the Czechoslovak government and Moscow ensued. Both Czech and Slovak communists encouraged Beneš to cede Subcarpathian Ruthenia. The Soviet Union agreed to postpone annexation until the postwar period to avoid compromising Beneš's policy based on the pre-Munich frontiers. The treaty ceding Carpathian Ruthenia to the Soviet Union was signed in June 1945. Czechs and Slovaks living in Subcarpathian Ruthenia and Ruthenians (Rusyns) living in Czechoslovakia were given the choice of Czechoslovak or Soviet citizenship.
Bulk vitrification uses electrodes to melt soil and wastes where they lie buried. The hardened waste may then be disinterred with less danger of widespread contamination. According to the Pacific Northwest National Labs, "Vitrification locks dangerous materials into a stable glass form that will last for thousands of years."
Sources: en.wikipedia.org
=== OECD === In October 2021, Castillo sent a letter to the secretary-general of the Organisation for Economic Co-operation and Development (OECD), Mathias Cormann, to ratify Peru's willingness to join the organization. In January 2022, Castillo signed the invitation letter to begin Peru's accession process to the OECD.
== Career == In 2001, Strahl joined the University of North Carolina at Chapel Hill as an assistant professor in the Department of Biochemistry and Biophysics. He was promoted to associate professor in 2008 and full professor in 2014. He also holds an appointment at UNC’s Lineberger Comprehensive Cancer Center and is a faculty member in the Curriculum in Genetics and Molecular Biology. Additionally, Strahl also serves as the faculty director of the UNC High-Throughput Peptide Synthesis and Array Core Facility From 2016 to 2020, he served as the Vice Chair of the Department of Biochemistry & Biophysics at UNC. From 2020 to 2022, he stepped into the role of Interim Chair of Biochemistry and Biophysics. Since 2023, Strahl has held the position of Assistant Dean for Research in the Office of Research at the University of North Carolina School of Medicine. The primary mission of the Office of Research is to develop and implement a strategic plan for research in the School of Medicine(reference). The UNC School of Medicine selected Strahl as an Oliver Smithies Investigator in recognition of his research contributions. This annual award recognizes senior faculty members who have gained international recognition for their work. Since 2015, Strahl has directed UNC's Program on Chromatin and Epigenetics, aiming to understand the complex language of epigenetic regulation. The program seeks to advance human health and address diseases. Stahl is also co-founder of EpiCypher, Inc. – a company known for services for chromatin biology and epigenetics research.
== Receptor oligomers == Heteromerization with other G protein-coupled receptors (GPCRs) produces complexes with differing ligand selectivity and signaling properties. They show altered G protein coupling, receptor trafficking, and tissue distribution compared to homodimers. Targeting specific KOR-containing heteromers with bivalent ligands may yield analgesics with fewer dysphoric effects, which could be relevant for addiction research and therapy. Heterodimer of KOR with δ-opioid receptor (DOR) is proposed to underlie the pharmacologically defined κ1 subtype and explain region-specific effects like analgesia or dysphoria. Besides KOR-DOR the receptor heterodimerizes with μ-opioid (preferentially forms in females), nociceptin (NOP), orexin receptor 1 (OX1), dopamine transporter (DAT), neurotensin 1, bradykinin B2, beta-2 adrenergic receptors, GPR88. With others possible but not yet definitely established.
=== Pharmacokinetics === After ingestion, bisoprolol is absorbed and has a high bioavailability of approximately 90% with a plasma half-life of 10–12 hours. Typically, half the circulating bisoprolol is metabolized by the liver, the rest passing unchanged through the kidneys before elimination; less than 2% may be excreted in the feces. Bisoprolol is soluble in both lipids and water. It is classified as a beta blocker with moderate lipophilicity and hence intermediate potential for crossing the blood–brain barrier. This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects than highly lipophilic beta blockers like propranolol but greater such effects than beta blockers with low lipophilicity like atenolol. The plasma protein binding of bisoprolol is approximately 35%, the volume of distribution is 3.5 L/kg and the total clearance is approximately 15 L/h. Bisoprolol is eliminated from the body in two ways - 50% of the substance is converted in the liver to inactive metabolites, which are then excreted in the kidneys. The remaining 50% is eliminated unchanged via the kidneys. Since elimination is equal in liver and kidney, no dose adjustment is required in patients with hepatic or renal impairment. The pharmacokinetics of bisoprolol are linear and independent of age. In patients with chronic heart failure, the plasma level of bisoprolol is higher and the half-life is longer than in healthy subjects when compared across studies.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.
No, NMN and NAD+ are different molecules. NMN is a precursor that cells can convert into NAD+ through enzymatic steps. NAD+ is a larger dinucleotide that serves as a coenzyme in many reactions.
Nicotinamide riboside, or NR, is another NAD+ precursor but has a different structure. NR lacks the phosphate group present in NMN. Both are studied for their roles in NAD+ metabolism, yet they enter cellular pathways in different ways.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.